35- COMPOSITION COMPRISING 35-DICAFFEOYLQUINIC ACID OR EXTRACT OF CHRYSANTHEMUM AS AN EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING OF MUSCULAR DISORDER OR IMPROVEMENT OF MUSCULAR FUNCTIONS
HWANG JAE KWAN,황재관,YUN JUN GON,윤준곤,KIM MI BO,김미보,KIM CHANG HEE,김창희,LEE JOON HYUNG,이준형,KWON JIN HYOUK,권진혁,YOON MANN SEOK,윤만석,LEE JIN WOO,이진우,LIM JAE YOUN,임재연,KO DONG HYEON,고동현,DOWAN KWON,권도완
申请号：
KR1020170162407
公开号：
KR1020180079174A
申请日:
2017.11.30
申请国别(地区):
KR
年份:
2018
代理人:
摘要：
The present invention relates to a composition containing a chrysanthemum extract and 3, 5-dicaffeoylquinic acid as active ingredients for preventing or treating muscular diseases, and more specifically, to a composition which reduces expression of mRNA of atrogin-1 and MuRF-1, which are major biomarkers involved in muscle protein degradation in muscle cells, and reduces muscle loss by increasing expression of an mTOR protein, which is a major biomarker involved in formation of a muscle protein, and expression of mRNA of myogenin and MyoD, which are biomarkers related to muscle differentiation, thereby being used for preventing and treating muscular diseases, or improving muscular functions. In addition, the chrysanthemum extract or 3, 5-dicaffeoylquinic increases activity of SIRT1 and PCG-1α, which are major biomarkers involved in exercise performance, thereby remarkably improving exercise performance. In addition, the composition of the present invention is a natural material and can be safely used without side effects, and is thus used for a medicine, food, or cosmetics.본 발명은 국화 추출물 및 3,5-디카페오일퀴닉에시드(3,5-dicaffeoylquinic acid)를 유효성분으로 함유하는 근육 질환 예방 또는 치료용 조성물에 관한 것으로, 구체적으로, 근육세포에서 근 단백질 분해에 관여하는 주요 생체지표인 atrogin-1과 MuRF-1의 mRNA 발현을 감소시키고, 근 단백질 형성에 관여하는 주요 생체지표인 mTOR 단백질과, 근육 분화 관련 생체지표인 myogenin과 MyoD의 mRNA 발현을 증가시킴으로써 근 손실을 감소시킬 수 있는 바, 근육 질환의 예방, 치료 또는 근 기능 개선에 이용될 수 있다. 또한, 상기 국화 추출물 또는 3,5-디카페오일퀴닉에시드는 운동수행능력에 관여하는 주요 생체지표인 SIRT1 및 PCG-1α의 활성을 증가시킴으로써, 운동수행능력을 탁월하게 향상시키는 효과가 있다. 또한, 본 발명은 천연물이므로 부작용 없이 안전하게 사용될 수 있어, 의약품, 식품 또는 화장품으로 사용될 수 있다.
